BioCryst and the Pan-Canadian Pharmaceutical Alliance (PCPA) Successfully Complete Negotiations for ORLADEYO (Berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals
Island Pharmaceuticals Signs Letteer of Intent to Acquire BioCryst's Antiviral Program
BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium
BioCryst Presents New ORLADEYO (Berotralstat) Data at 7th Bradykinin Symposium
Express News | BioCryst Appoints DR. Donald Fong Chief Medical Officer